Halozyme Therapeutics, Inc. vs. Krystal Biotech, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$106.12 -1.39%
VS KRYSKrystal Biotech, Inc. Common Stock
$337.02 -1.84%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| HALO | KRYS | |
|---|---|---|
| Market Cap | $12.21 billion | $10.16 billion |
| Revenue (TTM) | $1.66 billion | $440.48 million |
| Net Income (TTM) | $413.60 million | $241.47 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | KRYS | |
|---|---|---|
| P/E Ratio | 30.94 | 42.23 |
| Price / Book | 85.09 | 7.48 |
| Price / Sales | 7.34 | 23.07 |
HALO leads on 2 of 3 valuation factors.
Profitability
| HALO | KRYS | |
|---|---|---|
| Net Margin | 24.86% | 54.82% |
| Return on Equity | 288.13% | 17.77% |
HALO and KRYS split the profitability factors evenly.
Risk & Sentiment
| HALO | KRYS | |
|---|---|---|
| Short Interest | 9.79% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.